• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Fulcrum Therapeutics, Inc.

< Previous 1 2 Next >
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
November 09, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
November 07, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
October 31, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
September 22, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 15, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
September 07, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
August 22, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 11, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
August 03, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Appoints Chief Financial Officer
August 03, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET
July 27, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
July 10, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 07, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)
June 20, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 09, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023
May 15, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
May 15, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET
May 08, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 07, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces CFO Resignation
April 05, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 10, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
March 09, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
March 06, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
February 24, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
February 08, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
January 17, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
January 17, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 13, 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
< Previous 1 2 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap